What are the considerations for vaccination during pregnancy, including recommended inactivated vaccines, contraindicated live vaccines, and assessment of maternal immunization status?

Prenatal Vaccination Considerations

All pregnant women should receive inactivated influenza vaccine during any trimester and Tdap vaccine between 27-36 weeks of gestation, while strictly avoiding all live attenuated vaccines throughout pregnancy. 1

Routinely Recommended Vaccines During Pregnancy

Influenza Vaccine

• Timing: Any trimester of pregnancy 1
• Formulation: Only inactivated (trivalent or quadrivalent) virus vaccine
• Critical contraindication: Live attenuated intranasal vaccine is absolutely contraindicated due to theoretical risk of placental viral transmission 1
• Rationale: Pregnant women face 7.2% higher hospitalization rates and disproportionately high mortality from influenza, with infected women experiencing 10.7-fold increased risk of late pregnancy loss 1

Tdap (Tetanus, Diphtheria, Pertussis)

• Timing: Between 27-36 weeks gestation, as early in this window as possible 1, 2
• Frequency: During each pregnancy, regardless of prior vaccination history
• Alternative timing: Can be given earlier if needed for wound management or during pertussis outbreak 1

COVID-19 Vaccine

• Recommendation: Routinely recommended during pregnancy 3
• Safety: Initial data supports safe use of mRNA vaccines in pregnant women 1

RSV Vaccine

• Status: Now routinely recommended for all pregnant women in the United States 3

Vaccines Safe Under Special Circumstances

Risk-benefit assessment is essential for these vaccines—administer when maternal exposure risk outweighs theoretical vaccine concerns:

Hepatitis B

• Indication: High-risk patients or those requesting vaccination 1
• Safety: No association with adverse pregnancy outcomes 1
• Platform: Inactivated vaccine with aluminum hydroxide adjuvant (safe in pregnancy) 1

Meningococcal (Polysaccharide/Conjugate)

• Indication: High-risk women or outbreak settings 1
• Safety: No safety concerns; produces higher infant antibody concentrations 1

Hepatitis A

• Indication: After risk-benefit assessment for exposure 1
• Platform: Inactivated vaccine only; live attenuated contraindicated 1

Rabies

• Post-exposure: Never contraindicated given high case fatality rate 1
• Pre-exposure: May be considered for high-risk women 1
• Platform: Inactivated virus 1

Pneumococcal

• Indication: If maternal protection considered necessary 1
• Platform: Polysaccharide and conjugate vaccines (safe) 1

Travel-Related Vaccines (Inactivated Forms Only)

• Cholera: WHO recommends inclusion in vaccination campaigns; minimal risk with high benefit 1
• Polio (IPV): Routinely given in UK/New Zealand with Tdap; CDC recommends only for increased exposure risk 1
• Japanese encephalitis: Consider for endemic area travel with significant exposure 1
• Tick-borne encephalitis: Theoretically safe but no formal recommendations 1

Absolute Contraindications: Live Attenuated Vaccines

All live vaccines are contraindicated during pregnancy due to theoretical fetal infection risk: 4, 5

• Live attenuated influenza (intranasal)
• MMR (measles, mumps, rubella) - offer pre-pregnancy with 1-month pregnancy avoidance 4
• Varicella
• Live attenuated cholera 1
• Oral polio vaccine 1
• Live attenuated hepatitis A 1
• Live attenuated Japanese encephalitis 1
• Live attenuated Haemophilus influenzae type b 1

Critical Clinical Principles

General Safety Framework

Inactivated vaccines, toxoids, and immunoglobulins are safe during pregnancy; live vaccines are not. 6, 4, 2

• No evidence of adverse fetal effects from inactivated virus, bacterial vaccines, or toxoids 2
• Recombinant vaccines generally considered safe 1
• Aluminum hydroxide and CpG 1018 adjuvants are safe 1

Assessment Priorities

1. Routinely assess vaccination status at prenatal visits 2
2. Evaluate travel plans to endemic areas requiring specific immunizations 6
3. Identify high-risk exposures (occupational, household contacts, outbreaks) 1
4. Document previous vaccination history and immunity status 7

Common Pitfalls to Avoid

• Never delay influenza or Tdap vaccines waiting for "optimal" timing—give them when indicated 1
• Don't assume prior Tdap vaccination exempts current pregnancy—repeat each pregnancy 1, 2
• Avoid withholding indicated inactivated vaccines due to unfounded safety concerns 2
• Don't administer live vaccines even if inadvertent exposure historically showed no harm 1

Timing Nuances

• While Tdap can be given 27-36 weeks, earlier administration in this window is preferable 1
• For influenza, no consensus exists on optimal trimester, though third-trimester vaccination produces higher cord blood antibody titers; however, first-trimester infection carries greatest fetal risk, supporting earlier vaccination 1

Provider Responsibilities

Healthcare providers must routinely recommend and, when possible, directly administer needed vaccines rather than simply referring patients elsewhere 2. This direct engagement significantly improves uptake rates, which remain suboptimal (US influenza vaccine coverage: only 61.2%) 1.